NERVGEN PHARMA CORP. Form 6-K — Sep 25, 2026

Form 6-KFiled Sep 25, 2026, 4:30 PM ET0001104659-26-111004Original filing

NervGen Pharma's audit committee concluded on September 25, 2026 that previously issued financial statements for fiscal years 2024 and 2025, plus the Q2 2026 interim financials, should no longer be relied upon. The errors were non-cash valuation mistakes in accounting for stock options and derivative warrant liabilities, which overstated stock-based compensation expense and warrant liabilities.

AI analysis

Red flags3 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $49/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.